Mithra Announces Commercial Launch of Tibelia® in Canada

  • First tibolone-based hormone treatment available in Canada, offering a new treatment option for menopausal women
  • Mithra’s product commercialized by BioSyent Pharma for a growing annual market value of
    EUR 132 million
  • Canadian launch generates additional revenues for Mithra through sales related milestones

Liege, Belgium, 30 July 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the commercial launch of tibolone-based product Tibelia® in Canada. Developed by Mithra as the bioequivalent version of Livial®1, Tibelia® is a synthetic steroid that relieves postmenopausal symptoms and prevents osteoporosis in postmenopausal women at
high risk of future fractures who are intolerant of other medicinal products. Mithra’s product is marketed by BioSyent Pharma Inc. (TSX  Venture Exchange: RX) in Canada under the trademark name Tibella®.

Mithra’s EGM Approves Warrant Plan for LDA Capital

Liege, Belgium, 23 July 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that the Company’s Extraordinary General Meeting (EGM) held on 22 July 2020 approved the issuance of 690,000 warrants for the benefit of LDA Capital Ltd. The warrants were issued as part of the transaction announced on April 24 2020.

Mithra Signs License and Supply Agreement for Commercialization of Myring™ in Mexico

  • Mithra grants exclusive license to Megalabs for commercialization of its vaginal contraceptive ring in Mexico
  • Strengthening of the commercial presence in Latin and South America thanks to this second contract with Megalabs
  • Myring™ licenses granted to industry leaders in 35 countries, including the world’s three largest markets

Liege, Belgium, 14 July 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into a license and supply agreement (LSA) with Megalabs for the commercialization of its hormonal contraceptive ring Myring™ in Mexico. Based in Uruguay, Megalabs develops a wide range of market-leading pharmaceutical products in twenty Latin American countries

Publication of a Transparency Notification Received from Alychlo NV

Liege, Belgium, 10 July 2020 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from Alychlo NV, having its registered seat located at Lembergsesteenweg 19, 9820 Merelbeke, on 9 July 2020.

Publication of a Transparency Notification Received from Ogesip Invest SA

Liege, Belgium, 9 July 2020 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from Ogesip Invest SA, having its registered seat located at 1030 Schaerbeek Boulevard du Roi Albert II 37, on 30 June 2020.

Mithra Signs LSA for Commercialization of Myring™ in France, Poland and United Kingdom

  • Mithra grants license to Zentiva for commercialization of its vaginal contraceptive ring in three key European markets
  • Consolidation of commercial roll-out in Europe with 17 countries already under license
  • Production ongoing at Mithra CDMO for upcoming European commercial launches

Liege, Belgium, 06 July 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into a license and supply agreement (LSA) with Zentiva for the commercialization of its hormonal contraceptive ring Myring™ in France, Poland and the United Kingdom. Based in Czech Republic, Zentiva is a pharmaceutical company with more than 4,700 people and a network of production sites – including flagship sites in Prague, Bucharest, and Ankleshwar.

Mithra Announces FDA Filing Acceptance of New Drug Application for Estelle® in the US

Liege, Belgium, 24 June 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the New Drug Application (NDA) for Estelle® has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in the first half of calendar 2021.

Information on the Total Number of Voting Rights (Denominator)

Liege, Belgium, 23 June 2020 – 17:45 CEST –In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the following information, following the issuance of 3,421,052 new shares on 23 June 2020 for an amount of EUR 65.0 million in gross proceeds in the framework of the private placement via an accelerated bookbuild offering publicly announced on 18 June 2020.

Notice of Extraordinary Shareholders’ Meeting on 22th July 2020 Regarding Proposed Warrant Plans

Liege, Belgium, 19 June 2020 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the publication of the invitation to its Extraordinary General Shareholders’ Meeting (EGM) that will be held on Wednesday July 22 2020 at 2:00 PM (CET) in Flémalle 57 rue de l’Expansion (Belgium).

The agenda of this Meeting will mainly consider the issuance of two warrant plans subject to the shareholder’s approval : (i) one for the benefit of LDA Capital Ltd whereby a maximum of 690,000 warrants would be issued within the framework of the transaction announced on the 24th April 2020[1], and (ii) another for the benefit of reference shareholders (“Share Lending Warrants”) as further detailed in the supporting documentation for a maximum of 300,000 warrants.

The special reports of the board of directors and of the statutory auditor established pursuant to provisions 7:180, 7: 191 and 7:193 of the Belgian Companies and Associations Code, the notice for the EGM for the shareholders, including all details on how to participate to this Meeting and the supporting documents are available on the Company website.

[1] Press release Mithra, 24/04/2020

Mithra Successfully Raises EUR 65 Million By Means of a Private Placement via an Accelerated Bookbuild Offering

Liège, Belgium, 18 June 2020 20:30 CEST – Mithra Pharmaceuticals SA (the “Company” or “Mithra”), a company specialized in Women’s Health (Euronext Brussels: MITRA), announces today that it successfully raised an amount of EUR 65.0 million in gross proceeds by means of a private placement via an accelerated bookbuild offering of 3,421,052 new shares (being approximately 8.74% of the Company’s outstanding shares) at an issue price of EUR 19.00 per share (the “Private Placement“).

François Fornieri, CEO Mithra Women’s Health, commented: We are very pleased to have completed this transaction with an oversubscribed book of Tier 1 and specialist healthcare investors, and a competitive pricing. This private placement represents a key step in our funding strategy, carrying us through to commercialization of for our next-generation contraceptive Estelle®, as well as the further development of Donesta®, our novel product candidate for menopause.